Icecure Medical Ltd

ICCM | $1.23 -4.03% 120K

(0.0% 1d) (1.3% 1m) (-11.0% 1y) (0.0% 2d) (-6.2% 3d) (-11.0% 7d) (-91.45% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 56,116,824
https://icecure-medical.com
Sec Filling | Patents | n/a employees

Founded in 2006, Israel-based IceCure Medical develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide, after receiving FDA and CE approvals.

treatment cancer urea israel kidney lung cancer lungs

add to watch list Paper trade email alert is off

Lisata Therapeutics Inc

LSTA | $2.85 -5.82% 2K

Manufacturing

(0.0% 1d) (-19.4% 1m) (-17.6% 1y) (0.0% 2d) (-2.9% 3d) (-4.6% 7d) (-70.45% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 23,676,184
https://www.caladrius.com
Sec Filling | Patents | 24 employees

(US) Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).

treatment msa kidney lungs t-cell covid

add to watch list Paper trade email alert is off